HCWB

HCW Biologics Inc. [HCWB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HCWB Stock Summary

Top 10 Correlated ETFs

HCWB

In the News

HCWB Financial details

Company Rating
-
Market Cap
63.54M
Income
-24.8M
Revenue
2.84M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
45
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.1
Forward P/E
-
PEG
-0.3
P/S
14.34
P/B
1.72
P/C
-
P/FCF
-1.64
Quick Ratio
2.2
Current Ratio
2.56
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
70.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
55.2%
EPS Q/Q
114.29%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-42.86%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
-64%
ROC
-0.68%
Gross Margin
20%
Oper. Margin
-721%
Profit Margin
-681%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.91-2.32
52W High
-
52W Low
-
RSI
46
Rel Volume
1.55
Avg Volume
15.82K
Volume
24.49K
Perf Week
-2.53%
Perf Month
-15.2%
Perf Quarter
-37.7%
Perf Half Y
-47.97%
-
-
-
-
Beta
0.975
-
-
Volatility
0.03%, 0.25%
Prev Close
-1.03%
Price
3.85
Change
0%

Something similar

Top by Market Cap
0YXG.L
JPM
LLY.SW
3V64.DE
AAPL
Top Correlated ETFs
FIG
Same Price Range
PCF
2013.HK
002083.SZ
IBC3.DE
PETS
Similar Market Cap
SRT.L
3822.HK
GTII
SOSI1.HE
7261.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 15.82K
  • Market Capitalization 63.54M
  • Employee 45
  • CEO Dr. Hing C. Wong Ph.D.
  • Headquarters Miramar,FL,US
  • IPO Date 2021-07-20
  • Website https://www.hcwbiologics.com

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.